Clinical Trials for Non-Small Cell Lung Cancer

A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without Radiation Therapy for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients have stage IIIB-IV, PD-L1-negative (TPS <1%) non-small cell lung cancer without targetable EGFR, ALK, or ROS1 alterations and receive either standard immunotherapy (nivolumab [anti-PD-1] and ipilimumab [anti-CTLA-4], with or without chemotherapy) or the same systemic therapy plus short-course radiation to one tumor lesion. The trial excludes patients eligible for chemoradiation and follows them for survival and disease outcomes.

ClinicalTrials.gov ID: NCT04929041

A Phase II Study of Fingolimod in Patients With Non-Small Cell and Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial is enrolling adults with advanced/metastatic non-small cell lung cancer (any molecular subtype) or extensive stage small cell lung cancer who have progressed after at least two lines of systemic therapy, including chemotherapy and immunotherapy. Participants receive oral fingolimod, a sphingosine-1-phosphate receptor modulator with immunomodulatory and potential antitumor effects, as monotherapy.

ClinicalTrials.gov ID: NCT06424067

A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls patients with stage IV or recurrent NSCLC who have progressed after platinum-based chemotherapy and prior anti-PD-1 or anti-PD-L1 therapy, comparing standard docetaxel plus ramucirumab versus the same regimen with the addition of cemiplimab (an anti-PD-1 antibody) to assess benefit in the post-immunotherapy setting.

ClinicalTrials.gov ID: NCT06616584

ResQ201A: Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC who have progressed after one line of immune checkpoint inhibitor therapy, testing the combination of N-803 (an IL-15 superagonist that activates NK and CD8+ T cells), tislelizumab (anti-PD-1), and docetaxel versus docetaxel alone. Eligible patients may have any NSCLC histology or actionable mutations except ALK, and should have ECOG 0-2 and adequate organ function.

ClinicalTrials.gov ID: NCT06745908

A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates the combination of carfilzomib, a proteasome inhibitor, and sotorasib, a KRAS G12C inhibitor, in adults with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer who have progressed after previous KRAS inhibitor treatments.

ClinicalTrials.gov ID: NCT06249282

An Investigator-sponsored Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the efficacy of a combination of afatinib, an EGFR-targeting tyrosine kinase inhibitor, and prednisone in improving progression-free survival for patients aged 18 or older with previously treated advanced squamous non-small cell lung cancer. Enrolled patients must have an ECOG performance status of 0 or 1 and measurable disease.

ClinicalTrials.gov ID: NCT04497584

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves previously treated adult patients with stage IV ALK positive non-small cell lung cancer, evaluating the safety and optimal dosing of gilteritinib, an investigational drug that targets the FLT3 receptor tyrosine kinase. Patients must have progressed on first and second-generation ALK TKIs and may have had chemotherapy or other antineoplastic treatments.

ClinicalTrials.gov ID: NCT06225427

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and efficacy of combining pembrolizumab, a PD-1 inhibitor, with the experimental ornithine decarboxylase inhibitor DFMO in patients aged 18 or older with Stage IV NSCLC and STK11 mutations, focusing on those who are treatment-naïve or have progressed after previous therapies.

ClinicalTrials.gov ID: NCT06219174

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial evaluates the combination of Trans-Arterial Tirapazamine Embolization (TATE) and Pembrolizumab in patients with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) who have liver metastases and have progressed after prior therapies. TATE delivers the hypoxia-activated prodrug Tirapazamine to liver tumors, while Pembrolizumab, an immune checkpoint inhibitor, blocks the PD-1 pathway to enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT04701476

A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial enrolls patients with advanced or recurrent non-small cell lung cancer having EGFR mutations and MET amplification, who progressed after osimertinib, to assess the efficacy of capmatinib (a MET inhibitor) and osimertinib with or without ramucirumab (an anti-angiogenic antibody).

ClinicalTrials.gov ID: NCT05642572